Why the study?
Does aspirin or heparin-DHE prevent deep vein thrombosis in patients undergoing total hip replacement?
Does aspirin or heparin-DHE prevent deep vein thrombosis in patients undergoing total hip replacement?
Low-dose aspirin (250 mg/day) is an effective prophylaxis for deep vein thrombosis in patients undergoing total hip replacement.
Answers are grounded in this paper and cite their sources.
Aspirin was associated with lower DVT rates after hip replacement; leaves open whether it outperforms heparin-DHE in randomized trials.
A prospective study involving 120 consecutive patients undergoing total hip replacement was performed to compare the effectiveness of aspirin (high and low dose) or a combination of heparin plus dihydroergotamine (heparin-DHE) in preventing isotopic and phlebographic deep vein thrombosis (DVT), and to evaluate their effect on postoperative platelet changes. Phlebographic DVT was demonstrated in 9 cases (30%) in control group, in 1 (3.3%) in aspirin (high-dose) group (p less than 0.01), in 1 (3.3%) in aspirin (low-dose) group (p less than 0.01) and in 5 (16.6%) in heparin-DHE group (p = NS). Aspirin was able to reduce the postoperative increase in circulating platelet aggregates, platelet factor 4 and beta-thromboglobulin observed in control group. This study shows that aspirin is effective in the prevention of DVT for patients undergoing total hip replacement. Small aspirin dose (250 mg/day) represents an effective form of prophylaxis in these patients.
No takes yet. Share an insight, caveat, or question.
Alfaro et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: